Arovella Therapeutics (ASX: ALA)

Currency in -

Last close As at 22/09/2023


−0.01 (−25.00%)

Market capitalisation


Arovella Therapeutics is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system.

Latest Insights

View More

Healthcare | Flash note

Arovella Therapeutics — Strategic refocus on iNKT platform

Healthcare | Flash note

Arovella Therapeutics — Positive collaboration with ALA-101

Healthcare | Update

Arovella Therapeutics — Progressing on all fronts



Balance Sheet

Forecast net debt (A$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (5.6) 36.0 (15.0)
Relative 0.6 39.5 (11.6)
52 week high/low A$0.0/A$0.0


Edison Investment Research is terminating coverage on Arovella Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 0.3 (3.1) (3.4) (1.15) N/A N/A
2022A 0.3 (7.0) (7.4) (1.42) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A



SUDA Pharmaceuticals — Half-year update